Skip to main content
. 2017 May 11;12(5):e0176616. doi: 10.1371/journal.pone.0176616

Table 1. Patient characteristics according to the BMI level at start of dialysis.

    Body Mass Index (kg/m2)
Total
(n = 19 524)
<18.5
(n = 1 130)
[18.5–23[
(n = 5 326)
[23–25[
(n = 3 120)
[25–30[
(n = 5 483)
[30–39[
(n = 3 855)
≥40
(n = 610)
               
Men 63.3 46.4 62.8 71.5 69.3 57.9 35.9
Age (year) 54.9±11.9 49.7±14.5 51.6±13.5 55.2±11.5 56.9±10.5 57.9±9.6 57.0±9.8
BMI (kg/m2) 26.2±6.1 17.1 ± 1.2 21.1 ± 1.2 24.0 ± 0.6 27.3 ± 1.4 33.5 ± 2.6 44.6 ± 4.3
Denormalized eGFR (ml/min) 9.4±7.1 8.3±8.3 8.4±6.8 9.1±6.6 9.5±6.9 10.8±7.1 12.2±7.9
eGFR (CKD EPI) (ml/min) 8.0±6.0 9.2±7.2 8.1±6.4 8.0±6.1 7.8±5.6 8.1±5.5 8.2±5.4
Primary renal disease              
Polycystic kidneys 10.2 5.5 11.7 13.1 11.4 6.8 2.5
Glomerulonephritis 17.1 18.3 20.2 18.0 17.2 12.8 9.2
Vascular or hypertensive nephropathy 15.5 14.6 13.2 16.2 17.3 16.3 12.1
Diabetic nephropathy 23.5 10.6 14.3 18.2 24.0 38.9 52.6
Other or unknown 33.7 51.0 40.6 34.6 30.1 25.2 23.6
Comorbidities and disabilities              
Diabetes 35.6 16.7 21.2 27.5 38.0 58.0 73.9
Type 2 diabetes 30.3 10.6 14.2 22.2 33.7 53.9 71.0
Congestive heart failure 18.0 18.5 14.3 16.0 17.9 22.8 28.5
Coronary heart disease 17.9 10.8 13.0 16.6 20.2 24.0 21.0
Dysrythmia 10.1 7.1 7.0 8.8 11.4 13.7 13.9
Stroke or transient ischemic attack 7.9 7.4 7.0 7.9 8.0 9.3 7.4
Peripheral vascular disease 15.8 14.0 12.3 14.7 16.8 20.3 17.9
Active malignancy 7.8 11.8 9.0 8.4 7.2 5.7 4.8
Chronic respiratory disease 9.3 12.4 6.4 7.3 7.5 13.9 26.2
Liver disease 5.7 7.5 6.6 6.3 5.6 4.1 3.8
Amputation 2.2 2.2 1.5 1.8 2.2 3.3 4.6
Hemiplegia or paraplegia 1.9 2.4 2.0 1.8 1.8 1.6 1.7
Severely impaired vision 3.1 1.6 2.8 2.8 2.8 4.5 4.8
Severe behavioral disorder 3.3 6.6 3.5 3.0 2.5 3.3 2.7
Mobility              
Totally dependent for transfers 3.1 4.7 2.7 2.5 2.7 3.5 6.6
Need assistance mobility 6.5 9.4 5.8 5.9 5.4 7.2 14.8
Walk without help 90.5 85.9 91.5 91.6 92.0 89.3 78.6
Predialysis anemia care              
Hemoglobin <11 g/dl 35.0 30.7 33.6 36.3 37.4 34.7 28.8
Predialysis ESA treatment 49.5 47.2 47.5 48.5 50.8 51.4 52.2
Nutritional status              
Albuminemia (g/l) 33.8±6.9 31.9±7.9 33.5±7.1 33.9±7.0 34.4±6.8 34.2±6.1 32.9±6.1
Initial treatment condition              
Planned HD 59.1 51.7 56.0 58.8 60.2 63.5 64.0
Unplanned HD 28.4 36.5 30.5 27.7 26.1 26.5 32.1
Peritoneal dialysis 12.5 11.8 13.5 13.5 13.7 10.0 3.9
Weekly number of HD sessions              
    1–2 5.9 5.6 5.9 6.4 5.9 5.6 4.4
    3 93.0 93.0 93.2 92.7 93.0 93.2 93.4
    >3 1.1 1.4 0.9 0.9 1.1 1.2 2.3
Weekly HD session duration > 12 h 7.5 2.9 4.3 6.0 8.1 11.6 17.8

Abbreviations: eGFR, estimated glomerular filtration rate; ESA, erythropoietin stimulating agent; HD, hemodialysis; CKD–EPI, Chronic Kidney Disease Epidemiology Collaboration.

Mean±s.d. or %.